Olomorasib
Olomorasib is Lilly's KRAS G12C pill, designed to combine safely with immunotherapy in first-line lung cancer.
Second-generation covalent G12C inhibitor with a cleaner liver profile than sotorasib in combination with pembrolizumab (ORR 74% in first-line PD-L1 ≥50%, JTO 2025). Breakthrough Therapy designation with pembrolizumab in untreated KRAS G12C NSCLC and in KRAS G12C pancreatic cancer. Phase 3 SUNRAY-01 (first line ± chemotherapy) and SUNRAY-02 (early-stage) ongoing.
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Olomorasib" OR ABSTRACT:"Olomorasib" OR TITLE:"LY3537982" OR ABSTRACT:"LY3537982") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Olomorasib, not a curated reading list.